Friday , June 18 2021

Stem cells transplanted from IPS into the brain of a patient in Japan



This is a first world that gives hope to people with Parkinson's disease. On Friday, November 9, researchers from Kyoto University, Japan, said in a statement that successfully transplanted 2.4 million stem cell from iPS into the left brain of a patient with Parkinson's disease. "induced pluripotent stem cells" or, in French, induced pluripotent cells).

The operation, which took place last month, lasted three hours, says the medical team. The patient, a man of his fifties, was well tolerated. You will be under surveillance for two years. If there is no problem within six months, doctors will implant another 2.4 million additional stem cells, this time on the right side of the patient's brain.

Pluripotent stem cells

The second most common neurodegenerative disease of the nervous system after Alzheimer's disease, Parkinson's disease affects about 200,000 people in France and more than one million in Europe: 8,000 new cases are being reported each year in France. According to the US Parkinson's Disease Foundation. UU., The world has 10 million patients with Parkinson's.

Characterized by a progressive loss of neurons in the gray nuclei of the brain, Parkinson's disease causes a gradual loss of movement control and the appearance of other motor symptoms such as tremors and rigidity of the limbs. Currently, the treatments available "improve the symptoms, but without slowing the progression of the disease," says the Parkinson's Disease Foundation.

This new stem cell treatment of healthy donor iPS offers new hope for patients. In fact, the latter have the distinction of being pluripotent: being transplanted in the brain are capable of developing neurons that produce dopamine, a neurotransmitter involved in the control of motor skills.

Clinical trials on seven patients announced

This successful work by Japanese scientists will probably not be the last. Last July, the University of Kyoto announced that a clinical trial would be initiated with seven participants aged between 50 and 69. "I greet the patients for their courageous and determined participation," said Professor Jun Takahashi, quoted on Friday by the public television channel NHK.

This clinical trial in itself is based on an experiment carried out on monkeys with stem cells of human origin and reported in a journal of Nature magazine in August 2017. According to the researchers, this transplant improved the ability primates with a form of movement of Parkinson's motion. The survival of the cells ingested, by injection into the brain of the primates, was observed during two years without the appearance of a tumor.

Are you interested in this topic? Come discuss in our forum.


Source link